Originally published as JCO Early Release 10.1200/JCO.2007.11.9867 on July 30 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Advani, R. Articles by Horning, S. J. Search for Related Content PubMed PubMed Citation Articles by Advani, R. Articles by Horning, S. J. Social Bookmarking                            What's this?

Impact of Positive Positron Emission Tomography on Prediction of Freedom From Progression After Stanford V Chemotherapy in Hodgkin's Disease

Ranjana Advani, Lauren Maeda, Philip Lavori, Andrew Quon, Richard Hoppe, Sheila Breslin, Saul A. Rosenberg, Sandra J. Horning

From the Stanford University Comprehensive Cancer Center, Stanford, CA

Address reprint requests to Ranjana Advani, MD, Stanford University Medical Center, 875 Blake Wilbur Dr, Stanford, CA 94305; e-mail: radvani{at}stanford.edu

Purpose To correlate [¹⁸F]fluorodeoxyglucose positron emission tomography ([¹⁸F]FDG-PET) status after chemotherapy, but before radiation, with outcome in patients treated with the Stanford V regimen.

Patients and Methods We analyzed retrospectively 81 patients with Hodgkin's disease who had serial [¹⁸F]FDG-PET scans performed at baseline and again at the completion of Stanford V chemotherapy, before planned radiotherapy. Patients with favorable stage I/II (nonbulky mediastinal disease) and those with bulky mediastinal disease or stage III/IV were scanned after 8 and 12 weeks of chemotherapy, respectively. Radiotherapy fields were determined before starting chemotherapy based on baseline computed tomography scans.

Results After chemotherapy, six of 81 patients had residual [¹⁸F]FDG-PET–positive sites, all in sites for which radiotherapy was planned. Four of the six patients with positive [¹⁸F]FDG-PET scans after chemotherapy experienced relapse compared with just three of 75 patients with negative [¹⁸F]FDG-PET scans. At a median follow-up of 4 years, the freedom from progression (FFP) was 96% in postchemotherapy [¹⁸F]FDG-PET–negative patients versus 33% in [¹⁸F]FDG-PET–positive patients (P < .0003). In a bivariate Cox model, [¹⁸F]FDG-PET positivity after chemotherapy remained a highly significant predictor of progression-free survival even after controlling for bulky disease and International Prognostic Score more than 2.

Conclusion These data indicate that PET status after chemotherapy is strongly predictive of FFP with the Stanford V regimen despite the use of consolidative radiotherapy. These results have implications for the design of clinical trials adapted to functional imaging.

published online ahead of print at www.jco.org on July 30, 2007.

Presented in part at the Ninth International Conference on Malignant Lymphoma, June 7-10, 2005, Lugano, Switzerland.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Mocikova, P. Obrtlikova, B. Vackova, and M. Trneny Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study Ann. Onc., November 9, 2009; (2009) mdp522v1. [Abstract] [Full Text] [PDF]

				D. J. Sher, P. M. Mauch, A. Van Den Abbeele, A. S. LaCasce, J. Czerminski, and A. K. Ng Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy Ann. Onc., November 1, 2009; 20(11): 1848 - 1853. [Abstract] [Full Text] [PDF]

				PET and Prognosis in Hodgkin Lymphoma: Retrospective Analysis Journal Watch Oncology and Hematology, September 18, 2007; 2007(918): 1 - 1. [Full Text]